DUBLIN–(BUSINESS WIRE)–The “Atopic Dermatitis Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.
The report delivers an in-depth understanding of the AD, historical and forecasted epidemiology as well as the AD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The AD market report provides current treatment practices, emerging drugs, AD market share of the individual therapies, current and forecasted AD market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current AD treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Key Findings
- The market size of AD in the 7MM is estimated to be USD 15,026 Million in 2021.
- Currently, the treatment regimen of AD in the US involves the use of Topical treatment options such as emollients, topical corticosteroids (TCS) Topical calcineurin inhibitors (TCIs) and systemic treatment such as immunosuppressant, corticosteroids, Dupixent, Eucrisa (Crisaborole) 2% ointment, Corectim Ointment and others.
- Expected Launch of potential therapies such as B244, Lebrikizumab (LY3650150), Etrasimod (APD334), Abrocitinib/PF-04965842, FB825, Nemolizumab (CD14152), DS107, Bermekimab, KY1005, ARQ-151/ Roflumilast cream, and others may increase the market size in coming years.
- Throughout the study period, the United States accounts for the largest market size of AD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The US market accounted for USD 10,476 Million in 2021.
- Among the EU5 countries, Germany had the highest market size with USD 884 Million in 2021, while Spain had the lowest market size of AD with USD 448 Million in 2021.
- The Japanese AD market was USD 1,273 Million in 2021.
Forecasts
- The total market size of AD in the United States is expected to increase with a CAGR of 10.9% in the study period (2019 – 2032).
- The total market size of AD in EU5 is expected to increase with a CAGR of 9.7% in the study period (2019 – 2032).
- The total market size of AD in the Japan is expected to increase with a CAGR of 8.2% in the study period (2019 – 2032).
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. SWOT Analysis
6. Atopic Dermatitis Market Overview at a Glance
7. Disease Background and Overview
8. Treatment
9. Atopic Dermatitis Clinical Guideline: American Academy of Dermatology Association
10. Atopic eczema in under 12s: Diagnosis and management by NICE
11. Consensus-based European guidelines for the treatment of atopic eczema (atopic dermatitis) in adults and children
12. Treatment Algorithm
13. Epidemiology and Patient Population
14. Organizations contributing towards AD
15. Patient Journey
16. Marketed Drugs
17. Emerging Drugs
18. Potential of Current Therapies and Emerging Therapies
19. Atopic Dermatitis: Seven Major Market Analysis
20. Market Drivers
21. Market Barriers
22. Unmet Needs
23. KOL Views
24. Market Access and Reimbursement
Companies Mentioned
- Sanofi
- Regeneron Pharmaceuticals
- Pfizer
- Japan Tobacco and Torii Pharmaceutical
- Eli Lilly and Company
- AbbVie
- LEO Pharma
- Incyte Corporation
- Arena Pharmaceuticals
- Oneness Biotech
- Galderma
- DS Biopharma
- Janssen
- Kymab
- Arcutis Biotherapeutics
- Qurient
- Cara Therapeutics
- Vanda Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/dkdljp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900